DSM Venturing invests in ZeaVision Holdings

ZeaVision Holdings, Inc., maker of the EyePromise® brand of doctor-recommended nutraceuticals, has received an equity investment from DSM Venturing, the corporate venture arm of Royal DSM, the global life sciences and material sciences company.

ZeaVision President, Chris Barber, commented: "DSM has a long history of excellence and innovation in the nutrition industry. We are pleased to welcome DSM as a strategic investor which offers unique potential to strengthen ZeaVision's leadership position in the ocular nutrition market."

Greg McParland, Senior Investment Manager of DSM Venturing says: "This investment is at the core of our strategy to support emerging companies in our ecosystem and create new business opportunities. We commend ZeaVision for its innovative and science based approach to eye care and look forward to supporting the team in the expansion of their business."

Will Black, Vice President of Marketing for DSM Nutritional Products says: "DSM is excited to invest in the company. ZeaVision has made a significant contribution to expand research and scientific understanding of the role of nutrition in eye health."

 

Source:

ZeaVision

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New bioimaging device shows promise for detecting eye and heart conditions